Symptomatic treatment of seasonal or perennial rhinitis in adults, adolescents & childn 3-11 yr & acute rhinosinusitis in ≥12 yr w/o signs or symptoms of severe bacterial infection. Nasal polyps in patients ≥18 yr. Prophylaxis in patients w/ history of moderate to severe seasonal allergic rhinitis symptoms.
Seasonal allergic or perennial rhinitis Adult including geriatric & adolescent 2 sprays (50 mcg/spray) in each nostril once daily, may be reduced to 1 spray in each nostril as maintenance. Max: 4 sprays in each nostril once daily. Childn 3-11 yr 1 spray (50 mcg/spray) in each nostril once daily. Nasal polyposis Adult including geriatric & adolescent ≥18 yr 2 sprays (50 mcg/spray) in each nostril bd, may be reduced to 2 sprays in each nostril once daily. Acute rhinosinusitisAdult including geriatric & adolescent ≥12 yr 2 actuations (50 mcg/actuation) in each nostril bd.
Discontinue use if localized fungal nose or pharynx infection & persistent nasopharyngeal irritation develops. Not to be used in presence of untreated localized infection involving nasal mucosa; recent nasal surgery or trauma. Active or quiescent tuberculous resp tract infection or untreated fungal, bacterial, systemic viral infections or ocular herpes simplex; severe bacterial infection; periods of stress or elective surgery. Immunosuppressed patients. Visual disturbance. W/drawal symptoms during transfer from systemic corticosteroids. High-dose & long-term treatment. Women of childbearing potential. Pregnancy & lactation. Growth retardation in childn.
Sign Out
